Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2010) Joshua J Neumiller et al.   PHARMACOTHERAPY

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

(2010) Robert Frederich et al.   POSTGRADUATE MEDICINE

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

(2009) Mark Kirby et al.   CLINICAL SCIENCE

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2009) Richard E. Pratley et al.   CURRENT MEDICAL RESEARCH AND OPINION

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone

(2009) Priscilla Hollander et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE